Report #2839963

Received May 8, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: UT
Recovered: Recovered
Vaccinated: Apr 16, 2025
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	2	945664	IM / LA

Symptoms (4)

DyspnoeaErythemaPruritusUrticaria

Symptom narrative

A Red Face; Shortness of Breath; Itchiness; Hives; Initial report received on 17-Apr-2025. A reporter reported that a 19-year-old female (ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and developed hives, a red face, itchiness, and shortness of breath. No medical history was reported. No concomitant medications were reported. On 16-Apr-2025, the patient received dose 2 of a hepatitis B vaccine [HEPLISAV-B (lot #945664, expiration date 31-Jan-2027, NDC # 43528-003-01)] intramuscularly in the left deltoid. On an unknown date, after receiving dose 2 of HEPLISAV-B, the patient developed hives, a red face, itchiness, and shortness of breath. No other side effects were reported. No other information was available. Company Comment: The company assessed the events as non-serious.; Sender's Comments: The company assessed the events as non-serious.